Siamak Daneshmand, MD
Urology · Los Angeles, CANPI 1174546568
Payments from drug & device makers
Across 693 payments — averaging $5043.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Janssen Research & Development, LLC$2.7M
- QED Therapeutics, Inc.$221K
- E.r. Squibb & Sons, L.L.C.$164K
- Photocure Inc$133K
- Ferring Pharmaceuticals AS$110K
- KARL Storz Endoscopy-america$63K
- plus $130K from 28 others
Across 1 payment — averaging $2326.99 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- F. Hoffmann-la Roche AG$2K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Janssen Research & Development, LLC | 397 | $2,673,816 |
| QED Therapeutics, Inc. | 24 | $221,119 |
| E.r. Squibb & Sons, L.L.C. | 19 | $164,094 |
| Photocure Inc | 60 | $132,983 |
| Ferring Pharmaceuticals AS | 22 | $109,642 |
| KARL Storz Endoscopy-america | 11 | $63,222 |
| Ferring Pharmaceuticals Inc. | 41 | $45,846 |
| Pfizer | 9 | $15,276 |
| Janssen Global Services, LLC | 27 | $14,398 |
| Olympus Corporation Of The Americas | 21 | $13,104 |
| Urogen Pharma, Inc. | 7 | $11,059 |
| AstraZeneca | 4 | $6,350 |
| Guard Medical Inc. | 2 | $4,250 |
| Davol Inc. | 5 | $3,547 |
| Astellas Pharma Global Development | 3 | $3,512 |
| Astellas Pharma US Inc | 4 | $3,001 |
| Seagen Inc. | 2 | $2,894 |
| Verity Pharmaceuticals Inc. | 1 | $1,600 |
| Abbott | 1 | $1,235 |
| AbbVie | 9 | $956 |
| Eli Lilly | 2 | $913 |
| Johnson & Johnson | 1 | $620 |
| Medtronic | 8 | $449 |
| Olympus Corporation | 1 | $448 |
| Genentech USA, Inc. | 1 | $237 |
| Fennec Pharmaceuticals, Inc. | 2 | $187 |
| EMD Serono, Inc. | 1 | $147 |
| Bausch & Lomb Americas Inc. | 1 | $116 |
| Ferring International Center SA | 2 | $87 |
| Innovation Technologies Inc | 1 | $81 |
| Bayer | 1 | $57 |
| Merck | 1 | $44 |
| Genentech, Inc. | 1 | $24 |
| Roche Products Limited | 1 | $17 |
How this compares
$3,495,331 in reported general payments places this provider in the 95th percentile of 1,324 urology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other urology in Los Angeles
- Karim ChamieLos Angeles$4.3M
- Arnold ChinLos Angeles$3.5M
- John KowalczykLos Angeles$1.8M
- Arie BelldegrunLos Angeles$1.8M
- Mihir DesaiLos Angeles$1.7M
- Brian ShuchLos Angeles$1.5M
- David JosephsonLos Angeles$1.5M
- Saum GhodoussipourLos Angeles$1.1M
- Stuart HoldenLos Angeles$1.1M
- William AronsonLos Angeles$951K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.